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Many diseases are of early-life origin. Early 
diagnosis of diseases, toxic exposures, effects, 
and susceptibilities in the still-developing 
body of infants will be required to develop 
successful intervention and treatment strate-
gies to battle diseases. It is well documented 
that exposures to environmental chemical 
contaminants, including cigarette smoke con-
stituents, for example, have adverse effects 
on fetal development and result in unfa-
vorable health trajectories for affected chil-
dren (Apelberg et al. 2007a; Buczyńska and 
Tarkowski 2005; Mattison 2010; Miranda 
et al. 2009; Wigle et al. 2007). Long-term 
outcomes such as diabetes, obesity, and 
chronic heart and kidney diseases have all 
been hypothesized or postulated to have their 
basis in fetal and childhood exposure (Barker 
et al. 2002) and show an increased prevalence 
in children and newborns (Bloomgarden 
2004; Ferrara 2007). Therefore, the develop-
ment of early diagnostics as predictors for 
child health is of paramount importance to 
enable early intervention.
Umbilical cord blood (UCB) is a very 
attractive biological specimen, because rela-
tively high volumes (up to tens of milliliters) 
of this biofluid are available for sampling 
without posing an added risk and burden 
to the newborn or its mother in the process. 
In addition, it has the potential to inform 
about existing or potential future adverse 
effects. UCB is already in use for prediag-
nosis and treatment of immune deficiencies 
(Notarangelo 2010). However, its primary 
use at this time is for bone marrow transplan-
tation (Buchheiser et al. 2009).
Mass spectrometry (MS)–based proteom-
ics is a powerful technology, allowing for the 
identification and quantification of hundreds 
of proteins in parallel from a single sample 
without necessitating prior selection or exclu-
sion of potential analytical targets. It has been 
employed successfully for a diverse range of 
organisms, tissues, and biofluids (Aebersold 
and Mann 2003; Ahrens et al. 2010a, 2010b; 
Beck et al. 2011; Domon and Aebersold 
2010; Nilsson et al. 2010) and offers an 
ideal platform for fast identification of new 
protein markers for diseases or adverse expo-
sure (Lemos et al. 2010; Liumbruno et al. 
2010). For adult blood, there is a long tradi-
tion of analyzing serum proteins using two-
  dimensional gel electrophoresis (Hughes et al. 
1992) or shotgun proteomics (Omenn et al. 
2005; Pieper et al. 2003; Richter et al. 1999; 
Schenk et al. 2008; States et al. 2006), with 
continuous analytical improvements (Bell 
et al. 2009; Gaso-Sokac and Josic 2010; Rai 
et al. 2005). In contrast to adult blood, much 
less information is available for the cord blood 
proteome. Recently, two short overviews 
on cord blood proteomics were published 
describing 207 and 837 different proteins, 
respectively (Colquhoun et al. 2009; Song 
et al. 2009). Unfortunately, the latter report 
provided information on only 61 of the 837 
proteins. The identifiers of the 776 remaining 
proteins are not published.
More detailed investigations of the UCB 
proteome are needed to accelerate the pace of 
discovery and expand the spectrum of infant 
health diagnostics. In addition, the sampling 
of UCB for proteome studies has to be suc-
cessful within the limitations of clinical real-
ity and is therefore much more challenging 
than the analysis of adult blood. The aim of 
this study was to provide insights into several 
important aspects necessary to use the UBC as 
an effective source for protein-based biomark-
ers. As a first priority, we aimed to expand 
the knowledge on the detectable proteome in 
UCB, which can be obtained from a limited 
starting volume. This is especially important 
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Ba c k g r o u n d: Early diagnosis represents one of the best lines of defense in the fight against a wide 
array of human diseases. Umbilical cord blood (UCB) is one of the first easily available diagnostic 
biofluids and can inform about the health status of newborns. However, compared with adult 
blood, its diagnostic potential remains largely untapped.
oBjectives: Our goal was to accelerate biomarker research on UCB by exploring its detectable pro-
tein content and providing a priority list of potential biomarkers based on known proteins involved 
in disease pathways.
Me t h o d s : We explored cord blood serum proteins by profiling a UCB pool of 12 neonates with 
different backgrounds using a combination of isoelectric focusing and liquid chromatography cou-
pled with matrix-assisted laser desorption/ionization tandem mass spectrometry (MALDI-MS/MS) 
and by comparing results with information contained in metabolic and disease databases available 
for adult blood.
re s u l t s: A total of 1,210 UCB proteins were identified with a protein-level false discovery rate of 
~ 5% as estimated by naïve target-decoy and MAYU approaches, signifying a 6-fold increase in the 
number of UCB proteins described to date. Identified proteins correspond to 138 different meta-
bolic and disease pathways and provide a platform of mechanistically linked biomarker candidates 
for tracking disruptions in cellular processes. Moreover, among the identified proteins, 38 were 
found to be approved biomarkers for adult blood.
co n c l u s i o n s: The results of this study advance current knowledge of the human cord blood serum 
proteome. They showcase the potential of UCB as a diagnostic medium for assessing infant health by 
detection and identification of candidate biomarkers for known disease pathways using a global, non-
targeted approach. These biomarkers may inform about mechanisms of exposure–disease relation-
ships. Furthermore, biomarkers approved by the U.S. Food and Drug Administration for screening 
in adult blood were detected in UCB and represent high-priority targets for immediate validation.
key w o r d s : body fluid, diagnostics, disease, LC-MALDI-MS, pathways, proteomics. Environ Health 
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because large volumes of UCB are required 
to obtain sufficient stem cells for therapeu-
tic purposes (Buchheiser et al. 2009; Forraz 
and McGuckin 2011). Hence, reducing the 
required volume for diagnostic purposes to a 
minimum is highly desirable. Moreover, we 
compared the identified proteins with known 
and proposed biomarkers to provide a short 
list of potential biomarkers that form a basis 
for the exploration of molecular mechanisms 
of exposure-disease relationships.
Materials and Methods
Chemicals. All chemicals were obtained from 
Sigma-Aldrich (Sigma Aldrich, St. Louis, 
MO, USA) with the following exceptions: 
Sequencing-grade modified porcine trypsin 
was obtained from Promega (Madison, WI, 
USA), and Bradford reagent was purchased 
from Bio-Rad (Hercules, CA, USA).
UCB serum samples. The UCB serum 
samples were acquired from the cord blood 
cohort collection of the Baltimore Tracking 
Health-Related Environmental Exposures 
(THREE) study. This study was approved 
by the Johns Hopkins Medicine Institutional 
Review Board (IRB approval 04-04-22-02) 
and received a waiver from the Health 
Insurance Portability and Accountability Act 
(2002). The study showed U.S.-representative 
exposure levels (mean and maximum concen-
trations) of a) perfluorooctanoate (PFOA): 
1.6 ng/mL, 7.1 ng/mL; b) perfluorooctane 
sulfonate (PFOS): 5 ng/mL, 34.8 ng/mL; 
c) organochlorine pesticides (e.g., trans-non-
achlor): 94 pg/mL, 185.5 pg/mL; d) trans-
permethrin: 36.3 pg/mL, 34.8 ng/mL; 
e) polychlorinated biphenyls (PCBs) (e.g., 
di-ortho): 17.4 ng/g lipid, 176.5 ng/g lipid; 
and f) heavy metals (e.g., lead: 0.66 μg/dL, 
15.5 μg/dL; copper: 38.6 μg/dL, 265 μg/dL). 
Details on this cohort are described elsewhere 
(Apelberg et al. 2007a, 2007b; Herbstman 
et al. 2007; Neta et al.2011; Wells et al. 
2011). Of this cohort study, 12 samples (eight 
male and four female) (Table 1) were ran-
domly chosen for proteomic profiling. Using 
the Witter cord cradle (Witter et al. 2001), 
hospital-trained personnel collected the UCB 
by direct venipuncture of the umbilical vein, 
which assured that no maternal blood was 
present in the samples. In addition, analysis of 
the X:Y chromosome ratios in male newborns 
as described by Guerrero-Preston et al. (2010) 
further confirmed the absence of maternal 
blood. Up to five 10-mL UCB samples were 
collected per newborn and immediately stored 
at 4°C. Within < 3 hr, the refrigerated blood 
specimens were centrifuged at 1,000 × g for 
15 min to collect the serum. Serum samples 
were then fractionated and stored in 2-mL 
polypropylene cryovials at –80°C. For pro-
teomic analysis, frozen sample splits were 
shipped on dry ice to the Biodesign Institute 
at Arizona State University; the individual 
samples were thawed for the first time just 
before sample processing.
Preparation of reference pool samples 
and immunodepletion. Aliquots of 100 μL of 
each of the 12 individual UCB samples were 
pooled to obtain a composite sample with a 
protein concentration of 79 mg/mL protein 
as determined by Bradford assay. Of this pool, 
240 μL were taken and human serum albu-
min (HSA) depleted using a Vivapure anti-
HSA kit (VivaScience, Hannover, Germany) 
according to the manufacturer’s description. 
We chose not to further deplete the samples 
because several of the other highly abundant 
blood proteins often routinely depleted are 
either U.S. Food and Drug Administration 
(FDA)–approved adult blood biomark-
ers (Anderson 2010) or proposed biomarker 
candidates for diverse diseases or exposures 
(Colquhoun et al. 2009; Ehmann et al. 2007; 
Ward et al. 2006). The HSA-depleted pro-
teome fraction was then concentrated and 
desalted by ultrafiltration using the Vivaspin 
500 concentrators (MWCO 3kDa; Sartorius, 
Goettingen, Germany). The total volume of 
the resultant composite sample was 150 μL, 
with a protein concentration of 33 mg/mL.
Protein digest and sample fractiona­
tion. Proteins were denatured and reduced 
in 10 mM ammonium bicarbonate and 
0.05% sodium dodecyl sulfate with 10 mM 
dithiothreitol at room temperature for 1 hr. 
Alkylation of proteins was accomplished by 
incubation in 40 mM iodoacetamide for 1 hr 
at room temperature in the dark. Ten micro-
liters sequencing-grade modified porcine 
trypsine (1 mg/mL stock solution; Promega, 
Madison, WI, USA) was added, and the mix-
ture was incubated at 37°C overnight. Tryptic 
digests (100–500 μg) were then fractionated 
with the Agilent 3100 OFFGEL Fractionator 
using the 3100 OFFGEL Low Res Kit, pH 
3-10 (Agilent Technologies, Santa Clara, 
CA, USA). The isoelectric focusing (IEF) was 
performed without ampholytes and glycerol 
according to the manufacturer’s instructions 
for peptide focusing. In short, the peptides 
were separated in a linear gradient of up to 
8,000 V. The potential was kept at 8,000 V 
until 56,000 Vh was reached. The 12 IEF 
fractions were then extracted with 0.1% trif-
luoroacetic acid in 50% methanol, vacuum-
concentrated, and dissolved in 2% acetonitrile 
and 0.1% trifluoroacetic acid.
Reverse­phase liquid chromatography 
(RP­LC) separation and MS­analysis. For 
the RP nano-LC separation, a Tempo LC 
MALDI Spotting system (Applied Biosystems/
MDS SCIEX, Foster City, CA, USA) 
was used with a 2-μL injector loop and a 
Chromolith CapRod column (150 × 0.1 mm; 
Merck, Darmstadt, Germany). Separation 
was obtained by running a gradient at a 
2-μL/min flow rate. Solution A contained 2% 
LC-grade acetonitrile and 0.1% trifluoroacetic 
acid; solution B contained 98% acetonitrile 
and 0.1% trifluoroacetic acid. A 30-min 
gradient elution with the following param-
eters was used: 2% B (0.5 min), 2%→40% B 
(0.5–15 min), 40%→65% B (15–22 min), 
65%→80%  B  (22–24  min),  80%  B 
(24–26 min), 80%→2% B (26–28 min), 
2% B (28–30 min). The matrix-assisted 
laser desorption/ionization (MALDI) matrix 
solution (7 mg/mL recrystallized α-cyano-
hydroxycinnamic acid, 0.1% trifluoro-
acetic acid, 70% acetonitrile) was added 
post  column with a flow rate of 2 μL/min. 
Every 7 sec the combined eluate was auto-
matically spotted onto a matrix pre  spotted 
stainless steel MALDI target plate (Applied 
Biosystems/MDS SCIEX). For calibration, 
13 calibrant spots (ABI 4700 Mix) were added 
to each plate manually. All spotted samples 
were analyzed with a 4800 MALDI-tandem 
time-of-flight (TOF/TOF) mass spec  trometer 
(Applied Biosystems/MDS SCIEX). First, 
MALDI-MS spectra were acquired over a mass 
range of m/z 800–4,000 in positive-ion reflec-
tor mode using 70–500 laser shots/spectrum 
with a fixed relative laser power of 3,300 and 
a central biased spot search pattern. In each 
MS spectrum, up to 25 peaks were selected 
for MS/MS using an acquisition method that 
excluded ions with signal-to-noise (S/N) ratios 
of < 50. The precursor ion with the weak-
est S/N ratio was acquired first to achieve the 
maximum signal intensity for low-abundance 
peptides. Tandem MS mode was operated 
using air as the collision-induced dissociation 
gas and enabled metastable ion suppressor 
Table 1. Statistics of selected UCB donors.
Characteristics No. of donors
Maternal race
African American 6
Caucasian 5
Asian 1
Maternal education
≤ High school diploma 7
1–4 years of college 2
≥ 5 years of college 3
Health insurance status
Private 5
Medicaid 3
Uninsured 4
Body mass index
Overweight 1
Obese 3
Substance abuse
Smoking 2
Reported diseases during pregnancy
Anemia 1
Asthma 1
Thyroid condition 1
Sexually transmitted disease 1
Urinary tract infection 1
Maternal age (years) 17–36
Gestational age (days) 270–288Hansmeier et al.
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settings. The relative precursor mass window 
was set to 200 (full width half mass). The MS/
MS acquisition of selected precursors was set 
to a maximum of 2,500 shots/spectrum with a 
fixed relative laser power of 4,200.
Protein identification and pathway map­
ping. The combined MS/MS spectra were 
searched using ProteinPilot™ Software v3.0 
(version 3.01 prior to July 2009; Applied 
Biosystems/MDS SCIEX) with the imple-
mented Paragon and the Pro Group pro-
cessing algorithm against the human subset 
of the National Center for Biotechnology 
Information (Bethesda, MD, USA) non-
redundant protein database (downloaded 
on 7 January 2008) and the UniProt human 
proteome database (version from 20 March 
2009). Peptide and protein identification was 
carried out with ProteinPilotTM. Most search 
parameters are not user-adjustable but con-
fer to the molecular and cellular proteom-
ics guidelines (Carr et al. 2004). Adjustable 
search parameters included cysteine modifica-
tion by iodoacetamide, methionine oxidation, 
tryptic digestion, and thorough search with 
biological modifications ID focus. Additional 
information on the ProteinPilotTM algorithm 
is found in Shilov et al. (2007). Because the 
samples were obtained according to normal 
clinical procedures and settings, they may 
include proteins that were at least partially 
digested, proteolysed, or degraded during 
sample handling (Richter et al. 1999). To 
address this issue and also to identify partially 
digested proteins, additional database searches 
were performed allowing nonspecific diges-
tion as search parameter. This search strategy 
was successfully employed for the generation 
of a plasma proteome reference map (Adkins 
et al. 2002; Chan et al. 2004; Richter et al. 
1999). Protein identification was based on 
ProtScore unused score criteria (Pro Group 
Algorithm, ProteinPilotTM software; Applied 
Biosystems/MDS SCIEX). Only proteins 
identified with Protscore ≥ 1.3 and at least 
one unique peptide with ≥ 95% confidence 
were used for further analysis. False discovery 
rate (FDR) was estimated by a search against 
a randomized decoy database using the same 
parameters as the original search (Elias et al. 
2005) as well as using the MAYU approach 
(Reiter et al. 2009). 
Blast2GO software was used to extract 
gene ontology (GO) information for each pro-
tein (Götz et al. 2008) for functional char-
acterization. The resulting list was curated 
manually. Pathway information for the iden-
tified proteins was obtained by Basic Local 
Alignment Search Tool (BLAST searches 
of the proteins against the curated Kyoto 
Encyclopedia of Genes and Genomes (KEGG) 
database (Aoki-Kinoshita and Kanehisa 2007).
Supporting information. Beyond the 
results presented here and in the Supplemental 
Material  (http://dx.doi.org/10.1289/
ehp.1104190), the additional information 
(EHP_Appendix 1–4 and the spectral data 
folder) is available on our homepage http://
labs.biodesign.asu.edu/halden/publications/ 
(Hansmeier et al. 2012) and at http://pro-
teomecommons.org (ProteomeCommons.org 
2012) project UCB proteome. Appendix 1 
contains the extended version of the list of all 
identified UCB proteins and their descriptions. 
Appendix 2 lists those proteins that are shared 
between the UCB proteome and the proteome 
reported for adult blood. Appendix 3 lists UCB 
proteins assigned to GO category “multicellular 
organismal development” which are unique for 
UCB or shared with adult blood. Appendix 4 
shows a detailed overview of UCB proteins and 
their respective KEGG pathways involved.
Results
An important step forward for the evaluation of 
the diagnostic potential of the UCB proteome 
as a source of biomarkers is the comprehensive 
analysis of its protein composition, ideally with 
minimal bias from individual health histories. 
Therefore, we created pooled UCB composite 
samples from the THREE cohort study, which 
showed U.S.-representative exposure levels 
to a diverse range of environmental pollut-
ants, including PFOS, PFOA, organo  chlorine 
pesticides, permethrin, and PCBs, as well as 
heavy metals (see “Materials and Methods” and 
Apelberg et al. 2007b; Herbstman et al. 2007; 
Neta et al. 2011; Wells et al. 2011). Using a 
total of 240 μL of the composite sample as 
starting material, we acquired a total of 62,686 
MS/MS spectra from 12 different LC-MALDI-
TOF/TOF runs. Altogether 1,210 non-
redundant human proteins were identified 
with ≥ 95% confidence [see Supplemental 
Material, Table 1 (http://dx.doi.org/10.1289/
ehp.1104190), and Appendix 1, Hansmeier 
et al. 2012]. The associated FDR were esti-
mated to be 5.1% using a naïve target-decoy 
search and 0.049 [~ 0.002 PSM (peptide spec-
trum match) FDR] using MAYU. A subset of 
843 proteins was identified at the ≥ 99% con-
fidence level (~ 0.009 protein FDR, ~ 0.0005 
PSM FDR, MAYU).
Compared with the previously published 
UCB proteome (Colquhoun et al. 2009) 
generated using the same search algorithm 
and confidence cutoff at ≥ 95%, our data set 
represents an approximately 6-fold increase 
in the number of identified UCB proteins 
to date. We further compared the UCB to 
a non  redundant list of plasma proteins of 
adults using published data (Omenn et al. 
2005; Schenk et al. 2008). In addition, we 
compared our data with a recently published 
high-quality data set obtained by the meta-
analysis of 91 experiments (Farrah et al. 2011). 
In total we found 295 proteins shared between 
the UCB and adult proteomes (Figure 1A; 
see also Appendix 2, Hansmeier et al. 2012). 
The number of shared proteins is reduced 
slightly to 224 when only UCB proteins iden-
tified with 99% confidence are considered 
(Figure 1B). Thus, a subgroup of blood pro-
teins exists that can be consistently identified 
regardless of the methods and samples used.
The detected UCB proteome covered a large 
range of molecular weights (4.7–3,880 kDa, 
as calculated from the sequence of the pro-
teins). About 44.6% of the detected proteins 
are classified as extracellular [see Supplemental 
Material, Figure 1 (http://dx.doi.org/10.1289/
ehp.1104190)]. Further, 33.3% and 22.1% 
of the identified proteins were predicted to 
be intracellular or membrane UCB proteins, 
respectively. Similar distributions of extracel-
lular, intracellular, and membrane proteins 
were observed in adult blood of healthy donors 
(Schenk et al. 2008). The presence of these pro-
teins in blood is generally believed to be the 
result of cell lyses, tissue leakage or shedding 
from cell surfaces, and subsequent releases in 
the bloodstream (Adkins et al. 2002; Chan et al. 
2004; Schenk et al. 2008).
In general, protein biomarkers are most 
useful if their functions are known and thus 
can be mechanically linked to the molecu-
lar basis of adverse health effects. Functional 
assignments of the identified UCB proteins 
according to GO classification (Figure 2) 
revealed that a plurality of UCB proteins 
Figure 1. Comparison of the 95% (A) and 99% (B) confidence UCB proteome data sets (this study) with data 
sets generated from individual adult blood proteome studies (Omenn et al. 2005; Schenk et al. 2008) and a 
meta-analysis of high-quality data sets from the last 6 years (Farrah et al. 2011). 
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(23.8%) were involved in responses to dif-
ferent stimuli in particular immune responses 
(e.g., immunoglobulins, signal transduction 
proteins, and elements of the complement sys-
tem). Furthermore, a large number of proteins 
were involved in cellular (13.7%), regulatory 
biological (13.3%), and metabolic processes 
(11.8%). Several of these proteins are known 
to be actively secreted into the bloodstream—
for example, to maintain homeostasis in the 
body. An example is angiotensinogen, which 
is part of the renin–angiotensin system and 
regulates blood pressure. An interesting cat-
egory, especially with respect to child devel-
opment, is the GO class of multicellular 
organismal development, describing several 
critical proteins involved in embryonic skel-
etal/bone system development essential for 
fetal growth (see Appendix 3, Hansmeier et al. 
2012). About 8.6% of identified proteins 
belonged to this group, including homeobox 
protein DLX-6 (P56179), sickle tail protein 
homolog (Q5T5P2), and fetuin-A (P02765) 
(Graham 2002; Karamessinis et al. 2008; 
Semba et al. 2006). Although these proteins 
are not necessarily specific to the UCB pro-
teome, their importance for embryogenesis is 
well recognized.
Moreover, we organized the UCB pro-
teome into metabolic pathways according to 
the KEGG database to identify which cel-
lular processes may be traced using UCB. A 
total of 138 metabolic and signaling path-
ways were found to be active (Figure 3; see 
also Appendix 4, Hansmeier et al. 2012). 
This includes proteins involved in immune 
response pathways, in control of the circula-
tory, endocrine, digestive, nervous systems, 
and in cellular metabolism and catabolism. 
Furthermore, traceable proteins belonged to a 
diverse range of signaling pathways in devel-
opmental processes, for example, for calcium, 
MAPK (mitogen-activated protein kinases), 
WNT (signaling pathway first discovered 
in Drosophila melanogaster), and Jak-STAT 
(Janus kinase-signal transducer and activa-
tor of transcription). Moreover, 54 proteins 
were already assigned to known human disease 
pathways and might be relevant for tracking 
disease-related changes earlier in life associ-
ated with maturity-onset diabetes of the young 
(MODY), primary immunodeficiency, sys-
temic lupus erythematosus, ventricular/hyper-
tonic or dilated cardiomyopathy, diverse kind 
of cancers, or infectious diseases.
Finally, we identified proteins in UCB that 
already are approved as biomarkers in adults 
by the FDA [Supplemental Material, Table 2 
(http://dx.doi.org/10.1289/ehp.1104190)], 
including 38 proteins diagnostic of a diverse 
range of disorders, for example, artery and 
organ diseases and inflammation in adults 
(Anderson 2010).
Discussion
The rising prevalence of newborn diseases with 
long-term effects (Bloomgarden 2004; Ferrara 
2007), such as diabetes, obesity, and chronic 
heart and kidney diseases, is expected to usher 
in new methods of UCB screening for early 
diagnosis in neonates. The present data set 
represents an important step forward in char-
acterizing the proteome UCB composition 
and detecting candidate biomarkers therein. 
The high-confidence UCB data set (≥ 99% 
confidence, 1% protein FDR) of the UCB 
proteome is comparable in size with the high-
quality data set from Schenk et al. (2008). 
As expected, a significant portion (~ 25%) of 
the proteins detected in UCB was previously 
found in adult blood. Because only limited 
information is available regarding the concen-
tration range of UCB proteins, we estimated 
the depth of our analysis from known adult 
blood protein levels. For instance, among 
identified targets were titin and mitochon-
drial glycine amidinotransferase, two proteins 
known to occur in the low nanogram per mil-
liliter range (4–6.8 ng/mL) in blood (Farrah 
et al. 2011). Assuming that proteins occur 
at comparable levels in adult and fetal blood 
(i.e., within an order of magnitude), our data 
likely covered a dynamic range of about six 
to seven orders of magnitude, which is in line 
with prior reports on adult blood (e.g., Chan 
et al. 2004).
Figure 2. Classification of the UCB proteome 
according to GO.
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We demonstrated that as little as 240 μL 
cord blood serum is suitable for obtaining 
proteome information at confidence levels 
comparable with those attained in adult blood 
studies. Use of this relatively low sample vol-
ume is not anticipated to adversely affect the 
possibility of further diagnostic tests.
Because clinical approval and validation 
of biomarkers are costly and time consuming 
(Chao et al. 2010), prioritization is important. 
Of highest priority are UCB proteins already 
approved by the FDA for diagnosis in adults. 
Among these were protein biomarkers for differ-
ent organ diseases such as deficiency of thyroid 
binding (thyroxine-binding globulin), chronic 
kidney dysfunctions (cystatin C), hypercoagula-
tion disorders (plasminogen), and cardio  vascular 
diseases (apolipoprotein A1, B). In addition, 
deficiencies in coagulation factors X or VII may 
indicate bleeding disorders that, without proper 
therapy, can lead to liver failure, internal bleed-
ing, or sudden death (Morley 2011). It is con-
ceivable that these established biomarkers are 
also of diagnostic value in infants.
Second in importance are proteins with 
known functions in metabolic pathways to 
inform about disruptions of normal cellular 
processes. Although not approved by the FDA 
for diagnostic purposes, a number of the pro-
teins identified in the UCB proteome are either 
known to play a role in certain diseases or can 
be diagnostic of exposure to toxic substances. 
Among the proteins found in disease pathways 
is the cardiac ryanodine receptor 2, whose dys-
function is directly linked to cardiac arrhythmia 
and sudden heart failure (Betzenhauser and 
Marks 2010; Durham et al. 2007; Wehrens and 
Marks 2003). Also of interest are homeobox 
protein NKX6.1 for MODY (Donelan et al. 
2010); protein S and platelet-derived growth 
factor BB for acute kidney injury (Thurman 
et al. 2009); WNT target-gene promoter 
TBL1XR1 (F-box-like/WD repeat contain-
ing protein) for acute lymphoblastic leukemia 
(Parker et al. 2008); and proto-oncogene serine/
threonine-protein kinase PIM1, which is pro-
posed as a marker for mutated K-ras signaling 
activity in pancreatic cancer (Xu et al. 2011). 
Furthermore, peroxisome proliferator-activated 
receptor (PPAR) and calcium-signaling path-
ways are associated with metabolic diseases such 
as diabetes mellitus type 2 and cardiovascular 
disorders (Benkusky et al. 2007; Biscetti et al. 
2009; Bulhak et al. 2009). Platelet factor 4, pro-
platelet basic protein precursor, and comple-
ment component 3 are known to be diagnostic 
in a panel for acute lymphoblastic leukemia in 
children (Shi et al. 2009). Interestingly, lower 
adiponectin levels in UCB also have been found 
to be a predictor of adiposity in children at 3 
years of age (Mantzoros et al. 2009).
We also detected several proteins associated 
with different kinds of toxic exposures. Toxic 
exposures can often have varied unspecific 
effects on human health. Accordingly, their 
effects on the molecular level are largely 
unknown. Potential biomarkers of exposure 
identified in here include proteins involved 
in lipid metabolism disruptable by smoking 
(Craig et al. 1989), alcohol (Través et al. 2007), 
or bisphenol A exposure (Chou et al. 2011). 
Specifically, we detected all previously pro-
posed protein biomarkers of in utero exposure 
to tobacco products from maternal smoking 
(Colquhoun et al. 2009).
Other identified proteins of interest 
included alpha-fetoprotein, whose expression 
is affected by cigarette smoke exposure but has 
also been found to be elevated after exposure to 
dioxins and phenols (Colquhoun et al. 2009; 
El Far et al. 2006), and endothelin B, which 
is elevated after inhalation of diesel exhaust 
(Langrish et al. 2009; Peretz et al. 2008). 
Antenatal administration of the drug betame-
thasone was associated with an increase in UCB 
of retinol-binding protein, transthyretin, and 
transferrin (Georgieff et al. 1988). Increased 
levels of IgG were found to be associated with 
a range of environmental exposures—for exam-
ple, to mold (Rydjord et al. 2007), organo-
chlorines (Karmaus et al. 2005), tobacco-smoke 
products (Colquhoun et al. 2009), and methyl-
mercury (Nyland et al. 2011).
Overall, the presented data indicate that 
proteome analyses may provide a window to 
current physiological status of patients and 
also offer opportunities for detecting molecu-
lar malfunctions related to diseases. In par-
ticular, protein biomarkers with mechanistic 
linkage to disturbed signaling and metabolic 
pathways have proved to be of diagnostic 
value. Diagnostics in the form of protein assays 
provide a spectrum of clinical data, including 
information on acute events such as forecasting 
of coronary diseases, myocardial infarction, and 
cancer (Anderson 2010).
Ideally, the results of this study will be 
supplemented with quantitative information 
on a population basis. Knowledge of normal 
and aberrant protein abundance at the pro-
teome level, together with pathway-centered 
analyses of adverse health effects in diverse 
population, will continue to drive the develop-
ment of mechanistically based biomarkers of 
health status.
Conclusion
In this study, we furnish a comprehensive 
data set of proteins detectable in UCB by MS. 
Here, detected proteins shown previously to be 
of diagnostic value in adults are deemed to be 
of particular interest as biomarker candidates. 
This UCB proteome screen demonstrates the 
feasibility of viewing numerous indicators of 
health effects and diseases in infants, using a 
global approach. The data set obtained may 
serve as a platform for further targeted and 
quantitative analyses of UCB proteins.
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